Implications of Emerging Antiviral Agents for Influenza: Assessing the Evidence

1.25 CME
$0 FEE


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Target Audience

The intended audience for this activity is infectious disease specialists and other health care professionals involved in the treatment of patients with influenza.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Compare the efficacy and mechanisms of action of therapeutic agents in late-stage clinical trials to those currently available to prevent and treat influenza. 
  • Evaluate the latest clinical trial data regarding the therapeutic efficacy of agents in late-stage development for the treatment of influenza. 
  • Assess the effects of emerging influenza treatments for their ability to reduce clinical illness, the duration of illness, viral shedding, and complications.

Activity Chair

Frederick G. Hayden, MD, FACP, FIDSA
Professor Emeritus of Medicine
Stuart S. Richardson Professor Emeritus of Clinical Virology
University of Virginia School of Medicine
Charlottesville, VA


Aeron C. Hurt, PhD 
Associate Professor 
Senior Research Scientist, Head of Antiviral Susceptibility 
WHO Collaborating Centre for Reference and Research on Influenza 
Melbourne, Victoria, Australia

Michael G. Ison, MD, MS, FIDSA, FAST 
Professor, Divisions of Infectious Diseases and Organ Transplantation 
Northwestern University Feinberg School of Medicine
Medical Director, Transplant and Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center 
Chicago, IL

Nelson Lee, MD, MRCP(UK), FRCP(Lond), FIDSA 
Professor, Division of Infectious Diseases 
Department of Medicine 
University of Alberta 
Edmonton, Canada


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

This enduring material is approved for 1 year from the date of original release, February 1, 2019 to February 1, 2020.

How to Participate in This Activity and Obtain CME Credit

To participate in this activity, you must read the objectives, answer the pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 7 of 10 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

The articles in this monograph were composed by a medical writer, based on faculty presentations on October 5, 2018, during a live CME symposium at IDWeek™ 2018.

The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.

Activity Chair and Faculty report the following relationships

Frederick G. Hayden, MD, FACP, FIDSA 
Royalty Details: American Society for Microbiology
Consulting Fee: World Health Organization, University of Alabama Antiviral Drug Discovery and Development Consortium (SAB)
Consulting Fee (donated directly to charities): Sequirus, Shionogi 
Travel Support: Shionogi 
Non-paid Consultant: Genentech/Roche, Janssen, Toyama/Fujifilm, Vir, Visterra 
Data Safety & Monitoring Board (paid to institution): Celltrion, GlaxoSmithKline, Vaccitech

Aeron C. Hurt, PhD 
Contracted Research (paid to institution): AusBio, Romark, Shionogi

Michael G. Ison, MD, MS, FIDSA, FAST 
Royalty: UpToDate
Consulting Fee: Celltrion, Genentech/Roche, Janssen, Seqirus, Shionogi, Toyama/MediVector, VirBio
Contracted Research: Beckman Coulter, Cepheid, Chimerix, Emergent BioScience, Gilead, Janssen, Shire
Data Safety & Monitoring Board: GlaxoSmithKline, Shionogi

Nelson Lee, MD, MRCP(UK), FRCP(Lond), FIDSA 
Consulting Fee: Janssen, Seqirus, Shionogi
Travel support: Janssen, Seqirus, Shionogi

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose. 

Medical Writer reports the following relationship(s)

Valerie Zimmerman, PhD
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Offices of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2019 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at